Search Results Search Sort by RelevanceMost Recent Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363. Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347. Case and Commentary May 2019 Should Physicians Offer a Ventricular Assist Device to a Pediatric Oncology Patient With a Poor Prognosis? Angira Patel, MD, MPH, Anna Joong, MD, Efrat Lelkes, MD, and Jeffrey G. Gossett, MD When evaluating a 10-year-old with leukemia and chemo-induced heart failure for VAD placement, a team considers what to do. AMA J Ethics. 2019;21(5):E380-386. doi: 10.1001/amajethics.2019.380. AMA Code Says May 2019 AMA Code of Medical Ethics’ Opinions Related to Ethics of Life-Sustaining Technologies Rachel F. Harbut How should physicians researching life-sustaining technologies consider their duties to enrolled subjects? AMA J Ethics. 2019;21(5):E416-420. doi: 10.1001/amajethics.2019.416. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363.
Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347.
Case and Commentary May 2019 Should Physicians Offer a Ventricular Assist Device to a Pediatric Oncology Patient With a Poor Prognosis? Angira Patel, MD, MPH, Anna Joong, MD, Efrat Lelkes, MD, and Jeffrey G. Gossett, MD When evaluating a 10-year-old with leukemia and chemo-induced heart failure for VAD placement, a team considers what to do. AMA J Ethics. 2019;21(5):E380-386. doi: 10.1001/amajethics.2019.380.
AMA Code Says May 2019 AMA Code of Medical Ethics’ Opinions Related to Ethics of Life-Sustaining Technologies Rachel F. Harbut How should physicians researching life-sustaining technologies consider their duties to enrolled subjects? AMA J Ethics. 2019;21(5):E416-420. doi: 10.1001/amajethics.2019.416.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Apr 2016 Is Proxy Consent for an Invasive Procedure on a Patient with Intellectual Disabilities Ethically Sufficient? Commentary 1 Stephen Corey, MD and Peter Bulova, MD Women with intellectual disabilities should not be sedated for a pap smear without their assent, and the test’s risks and benefits should be weighed. AMA J Ethics. 2016;18(4):373-378. doi: 10.1001/journalofethics.2016.18.4.ecas3-1604.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.